YMAB vs. AUPH, NTLA, MRVI, ELVN, PAHC, ZYME, ABCL, REPL, COLL, and RCKT
Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Aurinia Pharmaceuticals (AUPH), Intellia Therapeutics (NTLA), Maravai LifeSciences (MRVI), Enliven Therapeutics (ELVN), Phibro Animal Health (PAHC), Zymeworks (ZYME), AbCellera Biologics (ABCL), Replimune Group (REPL), Collegium Pharmaceutical (COLL), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry.
Y-mAbs Therapeutics vs.
Aurinia Pharmaceuticals (NASDAQ:AUPH) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.
Aurinia Pharmaceuticals currently has a consensus price target of $11.50, suggesting a potential upside of 45.11%. Y-mAbs Therapeutics has a consensus price target of $20.89, suggesting a potential upside of 265.19%. Given Y-mAbs Therapeutics' higher possible upside, analysts clearly believe Y-mAbs Therapeutics is more favorable than Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.
Aurinia Pharmaceuticals has a net margin of -10.23% compared to Y-mAbs Therapeutics' net margin of -28.22%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Y-mAbs Therapeutics' return on equity.
Aurinia Pharmaceuticals received 441 more outperform votes than Y-mAbs Therapeutics when rated by MarketBeat users. Likewise, 73.38% of users gave Aurinia Pharmaceuticals an outperform vote while only 63.38% of users gave Y-mAbs Therapeutics an outperform vote.
Y-mAbs Therapeutics has lower revenue, but higher earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Y-mAbs Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aurinia Pharmaceuticals had 8 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 9 mentions for Aurinia Pharmaceuticals and 1 mentions for Y-mAbs Therapeutics. Y-mAbs Therapeutics' average media sentiment score of 0.87 beat Aurinia Pharmaceuticals' score of 0.35 indicating that Y-mAbs Therapeutics is being referred to more favorably in the news media.
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are held by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 22.5% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Aurinia Pharmaceuticals beats Y-mAbs Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Y-mAbs Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Y-mAbs Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:YMAB) was last updated on 2/22/2025 by MarketBeat.com Staff
